The groundbreaking success of Viagra undeniably reshaped the drug landscape, but investing in companies heavily reliant on off-patent versions presents a complex picture. Despite early earnings were significant, the cessation of patents and the appearance of discounted alternatives have eroded market share. Thus, a thorough evaluation of present fi